Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study

Onder, 2020, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA, 323, 1775 Pastor-Barriuso, 2020, Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study, BMJ, 371 Baden, 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med, 384, 403, 10.1056/NEJMoa2035389 Polack, 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Iversen, 2021, Extending the interval of COVID-19 vaccine regimens in individuals aged 80 years or older, Lancet Healthy Longev, 2, e529, 10.1016/S2666-7568(21)00205-1 Rockwood, 2005, A global clinical measure of fitness and frailty in elderly people, CMAJ, 173, 489, 10.1503/cmaj.050051 Olivier, 2008, The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them?, Ann Allergy Asthma Immunol, 100, 333, 10.1016/S1081-1206(10)60595-9 Parry, 2021, Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people, Immun Ageing, 18, 34, 10.1186/s12979-021-00246-9 Tut, 2021, Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study, Lancet Healthy Longev, 2, e544, 10.1016/S2666-7568(21)00168-9 Richards, 2021, Comparison of SARS-CoV-2 antibody response by age among recipients of the BNT162b2 vs the mRNA-1273 vaccine, JAMA Netw Open, 4, 10.1001/jamanetworkopen.2021.24331 Steensels, 2021, Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273, JAMA, 326, 1533, 10.1001/jama.2021.15125 Boyarsky, 2021, Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients, JAMA, 325, 2204, 10.1001/jama.2021.7489 Barros-Martins, 2021, Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination, Nat Med, 27, 1525, 10.1038/s41591-021-01449-9 Schmidt, 2021, Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination, Nat Med, 27, 1530, 10.1038/s41591-021-01464-w Gustafson, 2020, Influence of immune aging on vaccine responses, J Allergy Clin Immunol, 145, 1309, 10.1016/j.jaci.2020.03.017 Collier, 2021, Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2, Nature, 596, 417, 10.1038/s41586-021-03739-1 Müller, 2021, Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination, Clin Infect Dis, 73, 2065, 10.1093/cid/ciab381 Fink, 2018, The evolution of greater humoral immunity in females than males: implications for vaccine efficacy, Curr Opin Physiol, 6, 16, 10.1016/j.cophys.2018.03.010 Kurupati, 2016, Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood, Oncotarget, 7, 62898, 10.18632/oncotarget.11704